Source: Eur Respir J, 52 (2) 1701857; 10.1183/13993003.01857-2017
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Pierre-Simon Bellaye, Toyoshi Yanagihara, Elise Granton, Seidai Sato, Chiko Shimbori, Chandak Upagupta, Jewel Imani, Nathan Hambly, Kjetil Ask, Jack Gauldie, Marc Iglarz, Martin Kolb. Macitentan reduces progression of TGF-ß1-induced pulmonary fibrosis and pulmonary hypertension. Eur Respir J, 52 (2) 1701857; 10.1183/13993003.01857-2017

Member's Comments

No comment yet.

Related content which might interest you: Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis Source: Eur Respir Mon 2012; 57: 148-160 Year: 2012 Treatment with sildenafil for pulmonary hypertension in pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005 Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 40: 93-100 Year: 2012 Pulmonary arterial hypertension in combined pulmonary emphysema and fibrosis Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle Year: 2018 Treatment of pulmonary hypertension in chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313 Year: 2006 Accelerated ageing in idiopathic pulmonary fibrosis and pulmonary hypertension Source: International Congress 2018 – Accelerated ageing in lungs Year: 2018 The impact of emphysema in pulmonary fibrosis Source: Eur Respir Rev 2013; 22: 153-157 Year: 2013 Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity Source: Eur Respir J 2005; 26: 586-593 Year: 2005 Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant Source: Eur Respir J 2007; 30: 715-721 Year: 2007 Pulmonary hypertension in idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome Source: Eur Respir J 2010; 35: 105-111 Year: 2010 Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Pulmonary hypertension in sickle cell disease Source: Annual Congress 2007 - ACCP1 - Pulmonary hypertension in sickle cell disease Year: 2007 Bosentan for sarcoidosis associated pulmonary arterial hypertension (BoSAPH) was effective in advanced parenchymal lung disease Source: Annual Congress 2012 - Sarcoidosis Year: 2012 Diagnosis of pulmonary arterial hypertension in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 335s Year: 2005 Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema Source: Eur Respir J 2011; 37: 176-183 Year: 2011 Sarcoidosis-associated pulmonary hypertension Source: Eur Respir Monogr 2022; 96: 234-255 Year: 2022